ijms-logo

Journal Browser

Journal Browser

Tuberculosis: Host Immunity, Diagnosis and Treatment

A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Pathology, Diagnostics, and Therapeutics".

Deadline for manuscript submissions: 20 January 2026 | Viewed by 839

Special Issue Editor


E-Mail Website
Guest Editor
1. Departamento de Química Biológica, Facultad de Ciencias Exactas y Naturales, Universidad de Buenos Aires, Intendente Güiraldes 2160, Pabellón II, 4°piso, Ciudad Universitaria, Buenos Aires C1428EGA, Argentina
2. Instituto de Química Biológica de la Facultad de Ciencias Exactas y Naturales (IQUIBICEN), Facultad de Ciencias Exactas y Naturales, Universidad de Buenos Aires, Consejo Nacional de Investigaciones Científicas y Técnicas, Intendente Güiraldes 2160, Pabellón II, 4°piso, Ciudad Universitaria, Buenos Aires C1428EGA, Argentina
Interests: tuberculosis; mycobacterium tuberculosis; autophagy; cytokines; molecular diagnosis
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Mycobacterium tuberculosis (Mtb) has killed nearly 1000 million people since the 19th century. Currently, tuberculosis (TB) remains a major global health problem, ranking among the top ten causes of death worldwide. To achieve adequate disease control, confident diagnostics and treatment of latent infections are required. The human immune response against Mtb is highly complex, involving the participation of several different cell types and numerous immune mediators, with particular temporal dynamics on the host microenvironment. Despite the great strides made in the characterization of the acquired cellular response in TB patients, it remains to be elucidated what exactly constitutes a protective response or leads to disease pathology. Furthermore, how Mtb is able to evade host immune surveillance and persist is not yet fully elucidated. And although an affordable and effective treatment is available to fight this pathogen, TB, together with COVID-19 in 2020–2021, is the leading cause of death from a single infectious agent. Therefore, improvements in treatment are included among the central aims of developing new strategies against this disease. Accordingly, supplementing anti-TB therapy with host response modulators could augment standard TB treatment. In addition, host-directed therapies (HDT) might provide an unexploited approach as complementary anti-TB therapies, either by increasing the ability of the host immune system to eliminate mycobacteria or by limiting collateral tissue damage associated with infection. This research topic, therefore, welcomes the submission of research articles and reviews focused on the host immunity, diagnosis, and treatment of tuberculosis infection.

In this Special Issue, original research articles and reviews are welcome. Research areas may include (but are not limited to) the following:

  1. The immune response of the host against Mycobacterium tuberculosis, including cellular and immunological mechanisms involved in the host response against Mtb infection, cellular and molecular pathways that control the pathogenesis of Mtb infection, and the evasion of host immune responses.
  2. Novel methods to prevent and diagnose Mtb.
  3. New approaches to improve the treatment of tuberculosis infection, including host-directed therapies (HDT).

Dr. Veronica Edith Garcia
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • tuberculosis
  • immune response
  • diagnosis
  • treatment
  • antibiotics
  • resistance

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Review

15 pages, 4683 KB  
Review
Genetic Susceptibility to Tuberculosis and the Utility of Polygenic Scores in Population Stratification
by Mariia A. Dashian, German A. Shipulin and Andrei A. Deviatkin
Int. J. Mol. Sci. 2025, 26(19), 9544; https://doi.org/10.3390/ijms26199544 - 30 Sep 2025
Viewed by 528
Abstract
Tuberculosis (TB) is one of the leading infectious causes of mortality worldwide. Although a significant proportion of the population (up to 36%, depending on the region) is infected with the latent form of TB, only about one in ten of these people will [...] Read more.
Tuberculosis (TB) is one of the leading infectious causes of mortality worldwide. Although a significant proportion of the population (up to 36%, depending on the region) is infected with the latent form of TB, only about one in ten of these people will develop an active form of the disease in their lifetime. This is due to a complex interaction between the host’s genetic predisposition and environment. However, the genetic determinants of TB are not well established and have been insufficiently explored in previous genome-wide association studies (GWAS) with sparse and incongruent results. We reviewed recent evidence on host genetic susceptibility to TB, highlighting population-specific characteristics, host–pathogen coevolution, and the limitations of conventional GWAS approaches in terms of clinical and genetic heterogeneity. While rare variants with high penetrance, such as TYK2 P1104A, lead to monogenic susceptibility, most heritable risk results from the cumulative effect of numerous common variants. This cumulative effect may be summarized using polygenic risk scores (PRSs). Although their use has been proven for non-communicable diseases, PRSs are not applied to infectious disease susceptibility. To date, no PRS model for susceptibility to tuberculosis has been consistently validated. The development of PRSs for TB susceptibility is limited by phenotypic heterogeneity, population structure, and co-adaptation between host and pathogen. Another major challenge is to take into account the considerable influence of environmental factors. This difficulty in modeling environmental influences probably explains the current lack of a clinically applicable PRS for TB susceptibility. However, taking these caveats into account, polygenic models could improve risk stratification at the individual level compared to single-variant association and allow for earlier targeted treatment and prophylaxis. Full article
(This article belongs to the Special Issue Tuberculosis: Host Immunity, Diagnosis and Treatment)
Show Figures

Figure 1

Back to TopTop